Replimune surges after report FDA chief Makary may be ousted

Rudrabhishek Enterprises

08/05/2026 18:55

** Shares of biotech firm Replimune REPL.O rise 16.47% to $3.89

** U.S. President Donald Trump is planning to fire U.S. Food and Drug Administration Commissioner Marty Makary, the Wall Street Journal reports, citing people familiar with the matter

** Makary on Tuesday defended the regulator's decision to not approve REPL's drug, Tudriqev for advanced skin cancer

** Last month, the health regulator declined to approve the drug for the second time

** Including session's move, REPL down ~60% YTD

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))